News

Case Studies

Interactive Core Sales Aid (iCSA) iPad Application for a Top-Five Pharmaceutical Company

Viscira was challenged to adapt content from printed sales aid material and reimagine it in a way that would allow sales reps to engage more effectively with health care practitioners (HCPs) about a treatment regimen for chronic lymphocytic leukemia (CLL) without diluting key medical messages for the brand. One of the program goals was to inform and educate HCPs about a new dosing algorithm for the product.

 

Click here to read the full case study in PDF format.

An Integrated Digital Strategy: Multi-Channel Healthcare Professional Education Campaign for Dendreon

BUSINESS GOAL:

Increase awareness about PROVENGE® (sipuleucel-T) for metastatic, castrate-resistant prostate cancer as an important treatment option which utilizes the patient’s own immune system and extends survival.

OBJECTIVE:

Communicate the clinical value and efficacy of PROVENGE to healthcare professionals, including oncologists, hematologists, and urologists.

Click here to read the full case study in PDF format.

Disease Education Interactive Sales Aid Application for a Top-Five Pharmaceutical Company

Viscira was challenged to develop an innovative selling tool that the client’s field sales force could use to educate oncology HCPs about the histological characteristics of an aggressive type of breast cancer and the HER2 biomarker. The client wanted the app to address a common knowledge gap in the interpretation of diagnostic findings and to allow the sales force to “bring to life” key educational and marketing messages in a highly visual and convincing way.

 

Click here to read the full case study in PDF format.

Mobile iPad™ Product Education Application for Onyx Pharmaceuticals

 

 

Viscira was challenged to develop an innovative tool to be used by the Onyx Medical Science Liaison (MSL) Team to educate hematology health care professionals (HCPs) about the use of Onyx’s pipeline molecule, carfilzomib—a selective, next-generation proteasome inhibitor, as a potential new treatment option for multiple myeloma. The tool needed to not only facilitate dialogue and exchange in a novel way between the Onyx MSLs and target HCPs, but it also needed to provide the kind of flexibility that allows for effective interactions even in time-constrained settings.

 

Click here to read the full case study in PDF format.